Is individualized medicine more cost-effective? A systematic review. - Wikidata - awgldk - TriplyDB

Is individualized medicine more cost-effective? A systematic review.

Is individualized medicine more cost-effective? A systematic review.

http://www.wikidata.org/entity/Q38191496

about

Economic evaluations of personalized medicine: existing challenges and current developments Points to consider for prioritizing clinical genetic testing services: a European consensus process oriented at accountability for reasonableness.Concepts of 'personalization' in personalized medicine: implications for economic evaluation.Economic Evaluations of Pharmacogenetic and Pharmacogenomic Screening Tests: A Systematic Review. Second Update of the Literature.When is Genomic Testing Cost-Effective? Testing for Lynch Syndrome in Patients with Newly-Diagnosed Colorectal Cancer and Their Relatives.Economic evidence on identifying clinically actionable findings with whole-genome sequencing: a scoping review Economic Evaluation in Stratified Medicine: Methodological Issues and Challenges Implementing personalized medicine with asymmetric information on prevalence rates.Integrating precision cancer medicine into healthcare-policy, practice, and research challenges.Economics of stratified medicine in rheumatoid arthritis.Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet?Cost-Effectiveness of an Individualized First-Line Treatment Strategy Offering Erlotinib Based on EGFR Mutation Testing in Advanced Lung Adenocarcinoma Patients in Germany.Simulation modeling for stratified breast cancer screening - a systematic review of cost and quality of life assumptions.Cost and Cost-Effectiveness Assessments of Newborn Screening for Critical Congenital Heart Disease Using Pulse Oximetry: A Review.Long-term outcomes of elderly patients with CYP2C9 and VKORC1 variants treated with vitamin K antagonists.Economic evaluation of personalized medicine: a call for real-world data.Understanding barriers to the introduction of precision medicines in non-small cell lung cancer: A qualitative interview protocol.Precision Medicine: From Science To Value.The economic case for precision medicine.

P2860

Q26797183-6DC3A9CF-85D0-48FB-A0B6-F5350F699BA9 Q27324818-7F3E165D-6B1E-4A18-AB18-1803C53E1B08 Q35575935-155CBB82-CCFA-4757-8A3B-221458209A11 Q35890606-8A79BFF4-8AD1-4024-A3D4-672BDA99293D Q36157315-A532449C-AF7A-4EC9-9218-7D7329A30012 Q36304418-051FE6B2-B8F7-4BC7-A27F-35E7D3B08D5C Q36883280-050CC521-222F-4CFA-8BA0-C26A61ADE4C1 Q37188012-815E132F-BC72-4F16-9B63-5D3E37436D15 Q37360550-9967955C-A8B5-4478-9516-40F9AF9C8C13 Q38264743-3D75C2A2-7B1E-42B6-82D7-4DCFF9868E39 Q38671676-0BD25978-3183-483A-9F3B-2B145DE13E35 Q40829674-B5BC0811-934C-4F55-9C53-D7227C87D166 Q47094586-2660210C-AE27-4220-A1AD-FD50F9B5C5A8 Q47708208-92EC3D49-6B94-47A9-A4BA-0BAB2E67A266 Q47728750-9B5A8422-C002-4DD2-B064-DFA5615E0C9A Q51830348-00ED0C3A-2BA9-4A97-9F72-993CB14F84BF Q55007332-04A60790-2307-49D7-B660-F1B4B1FAF754 Q55072280-19DE695D-7C1C-4621-8ED1-63A98365405C Q55217201-A117EEDF-4CB7-42AF-9134-75636A38578F

P2860

Is individualized medicine more cost-effective? A systematic review.

http://www.wikidata.org/entity/Q38191496

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Is individualized medicine more cost-effective? A systematic review.

@en

type

label

Is individualized medicine more cost-effective? A systematic review.

@en

prefLabel

Is individualized medicine more cost-effective? A systematic review.

@en

P1433

Q38191496-59A1A972-CE44-49C3-83E4-EC20D359751D

P1476

Q38191496-7E9AE932-D940-40DD-8A50-81B8EF5192AE

P2093

Q38191496-050D7354-6A5A-47A2-ACF5-BF276DE694DD

Q38191496-609C8073-BD69-4E8E-84DE-F94FBECF0C48

Q38191496-A96CFF54-94EE-4B00-BDC5-64BA09831174

P2860

Q38191496-0186D442-ACB2-4CD6-B136-98E00732A512

Q38191496-02977C17-323E-4D74-A74D-CF48B1A94DCD

Q38191496-0589AA2A-5E79-4821-840C-A239BEC3EE14

Q38191496-05DC5035-C07C-4758-BEA6-1240E5A2CBED

Q38191496-09D3E5F6-FEDB-4722-9A3F-BB74D3111922

Q38191496-0C0C6B88-390C-447C-8192-D41F38A37A18

Q38191496-104971F6-1E15-4D9B-9CA1-DE1E0E3FC7AE

Q38191496-115382D5-E631-40DF-8B0C-242E927844EC

Q38191496-1455B6DC-3F61-4B65-9826-F0211B8614E6

Q38191496-1D981BB2-02F7-4F4E-B3C7-8612B0DC3D44

P2888

Q38191496-89818362-C92D-4DBF-B75C-9CC57ACBBEAA

P304

Q38191496-FC650E1B-9C6F-4481-ADDE-D0A9BB7B0BAB

P31

Q38191496-0131B4E3-82F1-4144-85F8-08234248B783

P356

Q38191496-D6220EEB-9A27-41B0-902F-93019DD71D99

P433

Q38191496-7D115275-1EC2-4E35-A741-6BBE2DCADCCE

P478

Q38191496-BBE65F20-C31F-41BA-98F7-FB157CD83426

P577

Q38191496-BE0708EC-C988-4468-86E6-E097EAE1DF84

P698

Q38191496-C60EB46B-406E-4888-8EBA-30FD7C15928D

P356

S40273-014-0143-0

P1433

PharmacoEconomics

P1476

Is individualized medicine more cost-effective? A systematic review.

@en

P2093

Katharina Schremser

http://www.w3.org/2001/XMLSchema#string

Maximilian H M Hatz

http://www.w3.org/2001/XMLSchema#string

Wolf H Rogowski

http://www.w3.org/2001/XMLSchema#string

P2860

Within a smoking-cessation program, what impact does genetic information on lung cancer need to have to demonstrate cost-effectiveness?

Cost-utility analysis of genetic screening in families of patients with germline MUTYH mutations

When is pharmacogenetic testing for antidepressant response ready for the clinic? A cost-effectiveness analysis based on data from the STAR*D study

Pharmacogenomics and public health.

Pharmacogenomics, evidence, and the role of payers.

Economic evaluation of 21-gene reverse transcriptase-polymerase chain reaction assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer in Japan.

Cost-effectiveness analysis of recurrence score-guided treatment using a 21-gene assay in early breast cancer

Economic evaluation of genomic test-directed chemotherapy for early-stage lymph node-positive breast cancer.

The long-term benefits of genotypic resistance testing in patients with extensive prior antiretroviral therapy: a model-based approach.

30 years of pharmaceutical cost-utility analyses: growth, diversity and methodological improvement.

P2888

s40273-014-0143-0

P304

443-455

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40273-014-0143-0

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P577

2014-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24574059

http://www.w3.org/2001/XMLSchema#string